key: cord-0761307-ji00rugv authors: Pitlick, Mitchell M; Sitek, Andrea N; Kinate, Susan A; Joshi, Avni Y; Park, Miguel A title: Polyethylene Glycol and Polysorbate Skin Testing in the Evaluation of COVID-19 Vaccine Reactions: Early Report date: 2021-03-26 journal: Ann Allergy Asthma Immunol DOI: 10.1016/j.anai.2021.03.012 sha: c78c50d49fae8b0dd1b8e9e99f066294d0bcca55 doc_id: 761307 cord_uid: ji00rugv nan In December 2020, the U.S. Food and Drug Administration (FDA) issued Emergency Use Moderna, and widespread vaccination is ongoing. Contraindications to vaccination include a history of immediate allergic reaction to a component or prior dose of an mRNA COVID-19 vaccine. 1 As of January 18, 2021, anaphylaxis to the Pfizer-BioNTech and Moderna vaccines have occurred at rates of 4.7 and 2.5 cases per million doses, respectively. 2 The mechanism of allergic reaction is unknown, although inactive vaccine components such as polyethylene glycol (PEG) have been proposed as possible culprit antigens. PEG is a primary ingredient in osmotic laxatives and a widely used excipient in many medications. It has not been previously used in vaccines, and the molecular weight and structure of the PEG 2000 used in the mRNA COVID-19 vaccines is distinct as compared to laxative preparations. 3 Allergy to PEG has been described, particularly with higher molecular weight concentrations. 4-6 A review of FDA adverse event reports from 2005 to 2017 showed an average of 4 cases of anaphylaxis to PEG per year. 5 Skin testing has been successfully used to confirm suspected allergy to PEG-containing laxatives and medications, and guidelines for skin testing with non-irritating concentrations of PEG 3350 and polysorbate are available. 5, 7 Recent expert opinion has also provided an algorithm that includes skin testing as part of COVID vaccine reaction evaluation, but the predictive values of PEG and polysorbate skin testing in relation to risk of hypersensitivity reaction to COVID-19 vaccines are still unknown. 8 We report the first 15 cases of PEG and polysorbate skin testing completed in patients who had allergic symptoms following their first dose of the mRNA COVID-19 vaccines or reported a PEG/polysorbate allergy prior to their first vaccine dose. Rochester, MN and Scottsdale, AZ. The clinical need for skin testing and test selection were provider-determined at the time of evaluation. PEG 3350 (MiraLAX) testing was performed using sequential skin pricks at 1.7 mg/mL, 17 mg/mL, and 170 mg/mL. Methylprednisolone acetate (PEG-containing), methylprednisolone sodium (control), and triamcinolone acetonide (polysorbate 80 containing) testing were performed starting with a skin prick at 40 mg/mL with subsequent 1:100 and 1:10 intradermals with an additional 1:1 intradermal for triamcinolone. Polysorbate 20 testing was performed as a 1:1 skin prick followed by 1:100 and 1:10 intradermals with a 0.5 mg/mL concentration with a sterile water diluent. This study was an IRBapproved retrospective chart review. Between 1/15/21 and 2/1/21, 15 patients underwent skin testing. 8 had testing due to a reaction to the first dose of COVID-19 vaccine, and 7 had testing prior to vaccination due to reported PEG/polysorbate allergies, the characteristics and skin testing results of which are presented in testing. It may be hypothesized in these cases that PEG is not the culprit antigen or that non-IgE mediated mechanisms such as complement activation related pseudoallergy are involved. Additionally, the short interval between reaction and skin testing may increase the risk of false negatives. A preliminary success has been seen with the safe administration of the second vaccine dose after negative skin testing following a possible first dose reaction. One area of uncertainty is the ability of skin testing to predict COVID-19 vaccine reactions in patients who report prior PEG/polysorbate allergies. Systemic reactions to PEG are dependent on a combination of the molecular weight and absolute amount of PEG in the culprit medication, which can differ significantly between injectable and oral forms of PEG. 4 Additionally, the threshold needed to induce a systemic reaction likely differs among individuals. 4 These facts make interpretation of skin tests difficult in patients who have yet to receive a COVID-19 vaccine. An additional area of interest has been the recognition of the innumerable medications and vaccines that contain PEG/polysorbate. 8 One of our patients with a COVID-19 vaccine reaction also reported a possible reaction to a polysorbate 80 containing influenza vaccine. The magnitude of risk these prior reactions confer upon individuals yet to receive a COVID-19 vaccine, and the ability of skin testing to quantify that risk, remains unclear. it is clear that the allergist will play an essential role in the COVID-19 vaccination effort. As vaccination numbers increase, the absolute number of adverse reactions will also increase, which will provide opportunities to both refine testing strategy (with no or limited testing potentially being the best strategy) and address vaccination hesitation, with the ultimate goal being accurate risk stratification and safe vaccine administration to the population as a whole. Interim clinical considerations for use of mRNA COVID-19 vaccines currently authorized in the United States-Appendix B Reports of Anaphylaxis After Receipt of mRNA COVID-19 Vaccines in the US Excipients in vaccines per 0.5 mL dose Polyethylene Glycol-Induced Systemic Allergic Reactions (Anaphylaxis) Immediate Hypersensitivity to Polyethylene Glycols and Polysorbates: More Common Than We Have Recognized Immediate-type hypersensitivity to polyethylene glycols: a review Practical Guidance for the Evaluation and Management of Drug Hypersensitivity: Specific Drugs mRNA Vaccines to Prevent COVID-19 Disease and Reported Allergic Reactions: Current Evidence and Suggested Approach Brighton Collaboration Working Group on Anaphylaxis. Can the Brighton Collaboration case definitions be used to improve the quality of Adverse Event Following Immunization (AEFI) reporting? Anaphylaxis as a case study The authors would like to acknowledge Drs. Matthew A Rank, Gerald W Volcheck, Alexei Gonzalez-Estrada, and James T Li for their contributions to this manuscript, including intellectual conception and critical review.